Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Krabbe Disease and GM2 Gangliosidosis

https://investors.polaryx.com/pr/polaryx-therapeutics-receives-us-fda-fast-track-designations-for-all-four-indications-to-be-evaluated-in-the-soteria-basket-trial

Polaryx Therapeutics has been granted Fast Track Designation (FTD) for PLX-200 for the treatment of Krabbe disease, GM2 Gangliosidosis and Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease). This treatment is being studied in their SOTERIA Phase 2 basket trial. The Fast Track program is a regulatory program that expedites the development and review of drugs intended to treat serious conditions and address unmet medical needs. This will help speed up and make the review process easier as they will have more regular contact with the FDA to ask questions and they can submit parts of the application as it is completed.